The Wall Street Journal reported Monday that Walgreens is in talks to purchase the portion of AmerisourceBergen it doesn’t already own. These talks “reduce the likelihood that WBA would be an acquirer of [Humana] or [WellCare] as we have speculated as a strategic response to” the CVS-Aetna deal, Ana Gupte, a Leerink Partners analyst, wrote on Monday, according to TheStreet.
Walgreens’ potential acquisition of AmerisourceBergen is “timed right as a response to the increasing competition and pressure from other vertical integrations across the healthcare industry, especially the CVS-Aetna announcement,” said Brad Haller, M&A director at West Monroe Partners, according to TheStreet.
AmerisourceBergen is Walgreens’ primary pharmaceutical drug distributor, and a deal between the two companies would lead to more immediate synergy and margin opportunities than the CVS-Aetna transaction, according to Mr. Haller.
More articles on payer issues:
Aetna’s former medical director says he never reviewed patient records before denying care
BCBS Association calls for ‘urgent’ stabilization of the ACA individual market
Molina’s operating loss balloons to $269M in Q4: 5 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
